PRM 125
Alternative Names: PRM-125Latest Information Update: 26 Apr 2023
At a glance
- Originator PRM Pharma
- Class Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hypertension
Most Recent Events
- 30 Mar 2023 PRM Pharma terminates phase III trial in hypertension in the US (NCT05195827)
- 20 Dec 2021 Phase-III clinical trials in Hypertension in USA (unspecified route) (NCT05195827)